Abeona Therapeutics Inc ROCE
Cos'è ROCE di Abeona Therapeutics Inc?
ROCE di Abeona Therapeutics Inc è -42.98%
Qual è la definizione di ROCE?
Il ritorno sul capitale investito (ROCE) è un rapporto finanziario che misura la redditività di un'azienda e l'efficienza con cui viene utilizzato il suo capitale.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE di aziende nel Health Care settore su NASDAQ rispetto a Abeona Therapeutics Inc
Cosa fa Abeona Therapeutics Inc?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Aziende con roce simili a Abeona Therapeutics Inc
- Turning Point Therapeutics Inc ha ROCE di -43.12%
- Cerevel Therapeutics ha ROCE di -43.07%
- Global Metals ha ROCE di -43.04%
- Forma Therapeutics ha ROCE di -43.04%
- Protalix BioTherapeutics ha ROCE di -43.03%
- HEXO Corp ha ROCE di -43.00%
- Abeona Therapeutics Inc ha ROCE di -42.98%
- Netlist ha ROCE di -42.93%
- The Very Good Food ha ROCE di -42.86%
- Ambow Education Ltd ha ROCE di -42.79%
- Amaero Intl Ltd ha ROCE di -42.78%
- Kismet Resources ha ROCE di -42.76%
- Artelo Biosciences ha ROCE di -42.69%